Needham named Mind Medicine (MNMD) a top pick for 2026 and added the stock to its Conviction List. The firm keeps a Buy rating on the shares with a $28 price target Mind has a “catalyst-rich” 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results